source
- Crystalys nets $130M more to push gout drug through late-stage testsThe startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in t…BioPharma Dive · 10d ago↗ source
- Job dissatisfaction and health care access uncertainty grows in the U.S., new study findsWhat Hawaii's wildfires can teach the nation about health recovery, 4.5 million people disenrolled from SNAP, and more health newsSTAT · 10d ago↗ source
- Novartis scraps mid-stage radiopharma asset as Pluvicto soarsThe discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.